Collagen Hydrolysates: A Source of Bioactive Peptides Derived from Food Sources for the Treatment of Osteoarthritis

• Published in: Medicines (Basel, Switzerland) Vol. 10; no. 9; p. 50
• Main Authors: Larder, Christina E., Iskandar, Michèle M., Kubow, Stan
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.09.2023; MDPI
• Subjects: amino acids; Analysis; Arthritis; Bioavailability; Care and treatment; Cartilage; Collagen; collagen hydrolysate; Cytokines; Diagnosis; Health aspects; human health; Metabolism; Osteoarthritis; Patients; peptide; Peptides; Phosphatase; Physical therapy; Proteins; Review; Risk factors; Signal transduction; Transcription factors; Tumor necrosis factor-TNF; Canada
• ISSN: 2305-6320; 2305-6320
• DOI: 10.3390/medicines10090050

Osteoarthritis (OA) is the most common joint disorder, with a social and financial burden that is expected to increase in the coming years. Currently, there are no effective medications to treat it. Due to limited treatment options, patients often resort to supplements, such as collagen hydrolysates (CHs). CHs are products with low molecular weight (MW) peptides, often between 3 and 6 kDa, and are a result of industrialized processed collagen. Collagen extraction is often a by-product of the meat industry, with the main source for collagen-based products being bovine, although it can also be obtained from porcine and piscine sources. CHs have demonstrated positive results in clinical trials related to joint health, such as decreased joint pain, increased mobility, and structural joint improvements. The bioactivity of CHs is primarily attributed to their bioactive peptide (BAP) content. However, there are significant knowledge gaps regarding the digestion, bioavailability, and bioactivity of CH-derived BAPs, and how different CH products compare in that regard. The present review discusses CHs and their BAP content as potential treatments for OA.